

LONG-CHAIN FATTY ACID OXIDATION DISORDERS

ORDER ID

For internal use only

Requisition Form

LC-FAOD Sponsored Testing Program TRF887-5

This requisition form can be used to submit an order for the Long-Chain Fatty Acid Oxidation Disorders Program, a sponsored testing program for genetic disorders brought to you by Ultragenyx Canada Inc.

INSTRUCTIONS: Review the ordering options and then complete all sections of this form. Your ordering option will be indicated in the test selection section.

ORDERING OPTIONS 1. LC-FAOD SPONSORED TESTING PROGRAM For individuals that meet the eligibility criteria below and wish to receive the program specific genetic testing panels. REQUIRED: You must select below the appropriate eligibility criteria for this patient. This program is available to patients in eligible countries who have completed the UltraCare Start Form for LC-FAOD or are suspected of having or have been diagnosed with a long-chain fatty acid oxidation disorder and a plasma acylcarnitine test has been ordered (regardless of result - abnormal or normal.) Please select at least one of the following and provide a copy of abnormal biochemical confirmatory labs, if available: The patient has completed the UltraCare Start Form for LC-FAOD Carnitine palmitoyltransferase (CPT) IA deficiency is suspected or diagnosed O Carnitine-acylcarnitine translocase (CACT) deficiency/Carnitine palmitoyltransferase (CPT) II deficiency is suspected or diagnosed O Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency/Mitochondrial trifunctional protein (TFP) deficiency is suspected or diagnosed O Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency is suspected or diagnosed Another cause for abnormal acylcarnitine analysis results consistent with a type of LC-FAOD is suspected or diagnosed. Please provide the suspected cause:

2. GENE-SPECIFIC FAMILY FOLLOW-UP TESTING

For relatives of program participants who received a Pathogenic/Likely Pathogenic result or approved VUS who want to receive gene specific family follow-up testing at no additional charge. Relatives do not need to meet the eligibility criteria listed above. Learn more at invitae.com/family.

PATIENT INFORMATION					CLINICIAN INF	ORMATI	ON
First name	MI	Last name		Organization name			
Date of birth (MM/DD/YYYY)	Biological sex M F	MRN (medi	cal record number)	Phone	F	ax	
			Caucasian Ashkenazi Jewish	Address		(City
Sephardic Jewish Indigenous	Mediterranean Other: State/Prov ZIP/Postal code			ZIP/Postal code	Country		
Phone Email address (report access after clinician releases)				Primary clinical contact	name (if different from orde	ering provider) NPI (US only)
Address City			Primary clinical contact	email address (for report ac	ccess)		
State/Prov ZIP/Postal code Country		ntry	Ordering provider (s	elect <u>one</u> ordering provider		ne checkbox before the name)	
Ship a kit to this patient (option	al) by faxing or er	nailing this co	mpleted form to Labcorp Genetics	Name	NPI (US only)		il address (for report access)
Kit type: OBuccal swab kit CShip to: OAddress above C		ss:		0			
CDC	CIMENIA	I CODMA		0			
Specimen type: Blood (3-mL	CIMEN IN			0			
We cannot accept blood or oral s recent leukocyte transfusion, or h extracted in a CLIA or other suite Details at: invitae.com/specime	istory of bone ma ably certified lab a	rrow/stem cell	/liver transplants. DNA must be	0			
Specimen collection date	(MM/DD/YYYY	r):					are access to order online)
Special cases: O History of	current hematolo	ogic malignan	cy in patient	Name	O Share this order with the primary clinical contact's default clinical team, manage at invalves Email address (for report access)		, 0
PARTNER CODE FAOD C, A (write in country code, two characters)				Name	Email address (for report access)		(for report access)



LONG-CHAIN FATTY ACID OXIDATION DISORDERS

				CLINICAI	HISTORY				
FAMILY HISTORY									
Is there a family histo	ry of disease	for which the patient is bein	g tested? (Yes ONo	If yes, describe below a	and attach pedi	gree and/or clinical notes.		
Relative's relationship to this patient	Maternal or paternal	Diagnosed condition		Age at diagnosis	Relative's relationship to this patient	Maternal or paternal	Diagnosed condition	Age at diagnosis	
PERSONAL HISTORY	,								
Is/was this patient affected or symptomatic?† O Yes O N Provide details in the required clinical history questions (if applicab									
REQUIRED CLINICAL									
Outcome of Newbor	n Screen (NE	BS)						ma acylcarnitines results,	
OPositive – Suspe	cted disorder	r:					y encouraged. These resu or the final interpretation	ults are helpful for variant	
Negative			_ '		e or confirmatory resu		in the imal interpretation	of the variant.	
OUnknown			_	sults unavail	,	s amacirca			
Outcome of confirm	atory testing l	(e.g. acylcarnitine test)							
OPositive – Disord		, , ,	What pror	npted you to	suspect this patient m	ay have a long	g-chain fatty acid oxidatio	n disorder? (Exclude PHI)	
Olnconclusive – E									
ONegative	71301dc1 (3)								
If confirmatory test v	was positive, etic test? (che	what is the reason for eck all that apply)							
O Payer requirement	nt								
ODifferential diagr	nosis (betwee	en LC-FAOD types)							
ODistinguish affec	ted versus ca	arrier status	Ongoing o	clinical featur	es: (check all that app	ly)			
OUnderstand dise	ase course/p	prognosis	Cardiomyopathy				Myoglobinuria		
OInform treatment decision			O Elevated creatine kinase				Peripheral neuropathy		
OGenetic counseling		OHepatomegaly				Reye like syndrome			
Oldentify at-risk family members			OHypoketotic hypoglycemia				O Rhabdomyolysis		
Research			O Liver failure				Retinitis pigmentosa		
Other:			Muscle myopathy				Other:		
				1					
OPTIONAL - REQUESTED VARIANTS FOR THIS PATIENT'S REPORT, IF KNOWN									
To have the presence or absence of specific variants commented on in this patient's report, provide the details below. For gene-specific family follow-up see Note under Test Selection.									
The proband's (individual with the variant) gene/variant information is needed for this request. Provide the Invitae Order ID RQ#:OR attach a copy of the outside lab results (required)									
Variant(s) (e.g. GENE c.2200A>T (p.Thr734Ser) NM_00012345) If left blank, all variants identified in the proband will be commented on. This patient's relationship to proband:						ationship to proband:			
(p) (v) (v) (v)			<u> </u>	OParent OSibling OGrar			bling OGrandchild		
							OChild OSe	•	



LONG-CHAIN FATTY ACID OXIDATION DISORDERS

LC-FAOD SPONSORED TESTING PROGRAM – Indicate test(s) to be performed below:							
Test code	Test name		genes	Gene list			
06165	0 06165 Invitae Fatty Acid Oxidation Defects Panel			ACAD9, ACADM, ACADS, ACADSB, ACADVL, CPT1A, CPT2, ETFA, ETFB, ETFDH, FLAD1, HADH, HADHA, HADHB, HMGCL, HMGCS2, MLYCD, NADK2, SLC22A5, SLC25A20, SLC25A32, SLC52A1, SLC52A2, SLC52A3, TANGO2			
00103	minute ratio reid Saluation Defects ranci	25					
ENE-SPE	,	STING For relati		SLC52A2, SLC52A3, TANG			

If an order is placed using an outdated test requisition form, we reserve the right to upgrade ordered tests to their current versions. View current requisition forms online at invitae.com/forms or consider placing your order online in the Invitae portal. Note: Test IDs containing add-on codes will include the original panel as well as the add-on.

Invitae is now part of Labcorp Genetics. By signing this form, the medical professional acknowledges that the individual/family member authorized to make decisions for the individual (collectively, the "Patient") has been supplied information regarding and consented to undergo genetic testing, substantially as set forth in Labcorp Genetics' Informed Consent for Genetic Testing (invitae.com/forms). Based on this consent, I acknowledge that I permit Labcorp Genetics to de-identify the patient's personal information. The medical professional will retain evidence that the patient consented to genetic testing. The Patient has been informed that Labcorp Genetics may notify them of clinical updates related to genetic test results (in consultation with the ordering medical professional as indicated) and has been informed that deidentified (also referred to as pseudonymized) patient data may be used and shared with third parties in connection with the Program, for research and commercial purposes. For orders originating outside the United States, the Patient has been informed that their personal information and specimen will be transferred to and processed in the United States. The medical professional warrants that (1) he/she will not seek reimbursement for this no-charge test from any third party, including but not limited to government healthcare programs; (2) participation in the Program will not influence his/her medical decisions; (3) he/she is not obligated to purchase or prescribe any product or service offered by a sponsor of the Program; (4) he/she is not obligated to participate in or to encourage patients to participate in any clinical trial or other research program conducted by a sponsor; and (5) he/she will participate in the Program in accordance with applicable laws. The medical professional consents to the sharing of organization and provider contact information with third parties, including commercial organizations, who may contact the medical professional directly in connection with the Program. If I

Medical professional signature (required)	Date (MM/DD/YYYY)